Efficacy and Safety of Cysteamine-Isobionic Amide Complex in the Treatment of Periorbital Hyperpigmentation

Periorbital hyperpigmentation is a common yet challenging cosmetic concern due to the thin, vascular, and pigment-prone nature of periocular skin, as well as its multifactorial etiology. Discoloration in this area can be driven by genetics, photoaging, dermal thinning, and pigmentary disorders, making treatment outcomes often unpredictable and temporary. The cysteamine–isobionic amide complex offers a novel, non-hydroquinone and non-retinoid approach, combining the multi-pathway pigment reduction of cysteamine with the barrier-supporting and pigment-evening properties of isobionic amide. This pilot study aimed to evaluate the safety, tolerability, and efficacy of the cysteamine-isobionic amide complex for periorbital hyperpigmentation using objective imaging and patient-reported outcomes. Seven participants self-administered treatment three to five times weekly for 10 weeks. Patient-reported outcomes demonstrated consistent improvements in pigmentation, radiance, and overall appearance, with 83.3% noting improvement in their primary concern and 100% indicating they would recommend the regimen. The treatment was well tolerated, with only one case of transient mild erythema. To our knowledge, this is one of the first studies to investigate the cysteamine–isobionic amide complex in the periorbital region, supporting its potential as a safe, at-home option for under-eye hyperpigmentation. Future controlled trials with larger and more diverse cohorts are warranted to confirm these preliminary findings and assess long-term efficacy.  .